SC order on Novartis will impact investment in India: USIBC

Over 40 countries including China, Russia and Taiwan have already granted a patent for Novartis' Glivec and India now stands out as unique for not granting a patent to this incremental innovation, the statement said.

MNC lobby upset over Novartis patent verdict

The SC judgment caps about seven year of tussle launched by Novartis seeking patent cover for its cancer medicine Glivec.

SC decision on Novartis to benefit poor patients: Pharma cos

Novartis, however, said: "This ruling is a setback for patients that will hinder medical progress for diseases without effective treatment options".

Supreme Court rejects Novartis cancer drug Glivec patent plea

Glivec, used in treating chronic myeloid leukemia and some other cancers, costs a patient about Rs 1.2 lakh/month, much higher than Rs 8,000 which is the price of the generic drug.